Cosmos Health Inc. (COSM)
| Market Cap | 15.30M +37.2% |
| Revenue (ttm) | 65.27M +19.9% |
| Net Income | -19.14M |
| EPS | -0.63 |
| Shares Out | 50.74M |
| PE Ratio | n/a |
| Forward PE | 3.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 529,470 |
| Open | 0.3064 |
| Previous Close | 0.3064 |
| Day's Range | 0.2971 - 0.3083 |
| 52-Week Range | 0.2805 - 1.3200 |
| Beta | 4.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine),... [Read more]
Financial Performance
In 2025, Cosmos Health's revenue was $65.27 million, an increase of 19.93% compared to the previous year's $54.43 million. Losses were -$19.14 million, -14.45% less than in 2024.
Financial StatementsNews
Cosmos Health pursues research, development financing program with EIB
Cosmos Health (COSM) announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development financing program with the European Investment Bank, EIB...
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program €25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D program Institutio...
Cosmos Health announces withdrawal of registration statement on Form S-1
Cosmos Health (COSM) filed with the U.S. Securities and Exchange Commission a request for withdrawal of the Company’s Registration Statement on Form S-1, originally filed on December 18, 2024 and…
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that ...
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is...
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 report EPS outlook upgraded: Zacks now expects Cosmos Health to c...
Cosmos Health sees over $2.5M incremental annual revenue from Cur18 in U.S.
Cosmos Health (COSM) announced that it is projecting Cur18b to generate over $2.5M in incremental annual revenue in the United States within the next 12 to 18 months, based on…
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced tha...
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinic...
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturin...
Cosmos Health announces planned U.S. market launch of Cur18b
Cosmos Health (COSM) announced the planned Q2 U.S. market launch of Cur18b, a next-generation curcumin supplement. Cur18b “enters the U.S. curcumin category as a science-driven alternative to conventi...
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a compositio...
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the...
Cosmos Health reports FY25 adjusted EPS (12c) vs. (65c) last year
Reports FY25 revenue $65.3M vs. $54.3M last year. Greg Siokas, CEO, stated: “2025 was the year Cosmos Health (COSM) proved its model. Not with promises – with numbers. We delivered…
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments
Scaled contract manufacturing division, securing long-term agreements for over 12 million units Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase order...
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units
CHICAGO, IL / ACCESS Newswire / April 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced tha...
Cosmos Health reports ‘no impact’ from Iran, MiddleEast conflict
Cosmos Health (COSM) confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company’s operations, supply chain, or business…
Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today confirmed tha...
Cosmos Health announces planned Q2 U.S. launch of Liv18
Cosmos Health (COSM) announced the planned Q2 U.S. launch of Liv18, a next-generation liver health supplement powered by BergacynFF, a patented botanical blend clinically demonstrated to reduce liver ...
Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction
Powered by BergacynFF ® , the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials. CH...
Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that...
Cosmos Health says to issue updated guidance following FY25 results
Cosmos Health (COSM) provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year...
Cosmos Health says evaluating potential monetization options
The company said: “At current trading levels, the Company’s shares trade at a significant discount to reported book value, and management believes the Company’s market capitalization does not fully re...
Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
Continues to deliver record revenue and improving operating metrics Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitab...
Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000
CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the pur...